ArticleNeuro-oncology2012
Thromboembolic disease in patients with high-grade glioma.
Article in Neuro-oncology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 70 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
70 citing papers in PubMed, 3 syntheses or guidelines pooled it, 150 citations in OpenAlex.
- Anti-epidermal growth factor receptor therapy for glioblastoma in adults.The Cochrane database of systematic reviews · 2020Pooled it
- Venous thromboembolism prophylaxis in brain tumor patients undergoing craniotomy: a meta-analysis.Journal of neuro-oncology · 2016Pooled it
- Tissue factor in tumor microenvironment: a systematic review.Journal of hematology & oncology · 2014Pooled it
- Phase II trial of triple tyrosine kinase receptor inhibitor nintedanib in recurrent high-grade gliomas.Journal of neuro-oncology · 2015Trial
- Venous thromboembolism in high grade glioma among surgical patients: results from a single center over a 10 year period.Journal of neuro-oncology · 2014Trial
- Anticoagulation Following Surgery for Glioblastoma: Case Report and Review of the Literature.Journal of neurological surgery reports · 2026Article
- Unconventional guardians of the brain: MAIT cells as emerging players in glioblastoma immunity.Frontiers in immunology · 2026Review
- Review of glioblastoma and systemic comorbidities.Frontiers in oncology · 2026Review
- Article
- Incidence of Venous Thromboembolism in Newly Diagnosed Glioblastoma and Associated Risk Factors: A Retrospective Chart Review.Current oncology (Toronto, Ont.) · 2025Article
- Hemorrhagic and ischemic risks of anti-VEGF therapies in glioblastoma.Cancer gene therapy · 2025Review
- Venous Thromboembolism in Patients with Glioblastoma: Molecular Mechanisms and Clinical Implications.Thrombosis and haemostasis · 2025Review
- Unlocking the therapeutic potential of tumor-derived EVs in ischemia-reperfusion: a breakthrough perspective from glioma and stroke.Journal of neuroinflammation · 2025Review
- Article
- Comparative safety analysis of bevacizumab and alkylating agent in glioblastoma management - What have we learned recently?Frontiers in pharmacology · 2025Article
- Risk of Postoperative Hemorrhage After Glioma Surgery in Patients with Preoperative Acetylsalicylic Acid.Cancers · 2024Article
- Identification of a coagulation-related gene signature for predicting prognosis in recurrent glioma.Discover oncology · 2024Article
- Heparin interferes with the uptake of liposomes in glioma.International journal of pharmaceutics: X · 2023Article
- Epidemiology, biology, and management of venous thromboembolism in gliomas: An interdisciplinary review.Neuro-oncology · 2023Article
- The Role of EGFR Amplification in Deep Venous Thrombosis Occurrence in IDH Wild-Type Glioblastoma.Current oncology (Toronto, Ont.) · 2023Article
10 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Venous thromboembolism (VTE) is common throughout the course of disease in high-grade glioma (HGG). The interactions between the coagulation cascade, endothelium, and regulation of angiogenesis are complex and drive glioblastoma growth and invasion. We reviewed the incidence of VTE in HGG, the biology of the coagulome as related to glioblastoma progression, prevention and treatment of thrombosis, and the putative role of anticoagulants as anti-cancer therapy. VTE can be significantly reduced during the postoperative period with adherence to the use of mechanical and medical thromboprophylaxis. Activation of the coagulation cascade occurs throughout the course of disease because of a variety of complex interactions, including tumor hypoxia, upregulation of VEGR expression, and increases in both tumor cell-specific tissue factor (TF) expression and inducible TF expression in numerous intrinsic regulatory pathways. Long-term anticoagulation to prevent VTE is an attractive therapy; however, the therapeutic window is narrow and current data do not support its routine use. Most patients with proven symptomatic VTE can be safely anticoagulated, including those receiving anti-VEGF therapy, such as bevacizumab. Initial therapy should include low molecular weight heparin (LMWH), and protracted anticoagulant treatment, perhaps indefinitely, is indicated for patients with HGG because of the ongoing risk of thrombosis. A variety of coagulation- and tumor-related proteins, such as TF and circulating microparticles, may serve as potential disease-specific biomarkers in relation to disease recurrence, monitoring of therapy, and as potential therapeutic targets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.